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Despite the challenges communities continue to face related to the negative 
consequences of the trafficking and use of illicit drugs and the continued availability of 
illicit drugs across the Nation, over the past year we have seen significant progress in 
strengthening communities across the Nation to address this evolving crisis. The Trump 
Administration remains focused on making continued progress in its second National Drug 
Control Strategy dedicated to reversing the adverse impacts of addiction so we may continue 
to save American lives and set our Nation on a path to being stronger, healthier, and drug-
free. 
This Strategy focuses Federal government efforts along three complementary lines 
of effort. First, we must continue to prevent initiates to drug use through education and 
evidence-based prevention programs. Second, we must continue to reduce barriers to 
treatment services so that access to long-term recovery is available for those suffering from 
substance use disorder. And finally, we must continue our work to drastically reduce the 
availability of these drugs in the United States through law enforcement and cooperation 
with international partners to eliminate the negative effects that drug trafficking has on the 
safety of our communities and the well-being of our citizens.
Drug misuse and abuse continues to endanger too many communities, ruin too 
many families, and takes the lives of too many of our fellow Americans.  Drug addiction is 
causing rises in the number of children in foster care, job insecurity, and transportation 
safety issues.  While this Strategy reflects the President’s top priority to address the current 
opioid crisis and reduce the number of Americans dying from these dangerous drugs, it 
also sets us on the path to develop further the capability, knowledge, and infrastructure 
to respond quickly to the evolving nature of our Nation’s drug threats. It reflects our 
understanding of the complex interplay between the availability of drugs in the U.S. market 
and their use, anticipates changes in the drug environment in both the public health and law 
enforcement domains, and allows us to adapt our actions and make lasting progress against 
this historic national security, law enforcement, and public health challenge.
 Most importantly, it demands our full effort and a relentless focus on delivering 
results. The American People should expect nothing less.
James W. Carroll
Director of National Drug Control Policy
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“Our Administration remains committed to protecting 
American families and communities from the dangers 
of substance use. Working together we will lead our 
Nation to become a stronger, healthier, and drug-free 
society.”
—PRESIDENT DONALD J. TRUMP
INTRODUCTION
During the past year we have indeed made some progress in preventing drug use, reducing barriers to 
treatment leading to long-term recovery, and reducing the availability of drugs in our communities and 
our homes. The Trump Administration has made life-saving gains through the synchronized approach 
laid out in the final report of The President’s Commission on Combating Drug Addiction and Opioid Abuse 
in 2017, President Trump’s Initiative to Stop Opioid Abuse and Reduce Drug Supply and Demand in 2018, 
and the Administration’s 2019 National Drug Control Strategy. Nevertheless, far too many Americans 
continue to lose their lives to drug use, and drugs remain all too available throughout our Nation. While 
some advances have been made in our daily work to address the country’s unprecedented drug crisis, 
we remain far from achieving the President’s vision of being a healthier and drug-free society. 
We must continue the hard work of individuals and organizations at all levels of government and civil 
society in an effort to resolve the crisis and to save American lives. It is well-understood that the crisis 
has evolved over several decades and has steadily worsened with time. Every state and county, and 
every socioeconomic group in our country, continues to be affected by the negative consequences of 
illicit drug use. However, as in the past year, our long-term success can only be achieved by our collective 
commitment to save lives and establish lasting solutions to this historic problem. The partnership 
of our law enforcement and public health professionals, working side-by-side, and inspired by the 
strength and wisdom of families who have lost loved ones to the scourge of drug use, continue to make 
a significant difference. This National Drug Control Strategy, the Trump Administration’s second, affirms 
the President’s priorities for addressing the challenge of drug trafficking and use, now and in coming 
years. It also provides the strategic direction necessary for the Federal government to prevent initiates 
to drug use through education and evidence-based prevention, provide treatment for those suffering 
from the disease of addiction so they can reach long-term recovery, and reduce the availability of these 
dangerous drugs in every American community. 
The President’s top priority remains, as he articulated in his first strategy, to address, head on, the 
current opioid crisis and reduce the number of Americans dying from these dangerous drugs. In 2017, 
there were more than 70,200 drug overdose deaths in the United States.1 More than 47,500 of these 
deaths involved an opioid, and more than half of these deaths involved a synthetic opioid such as 
illicit fentanyl or one of its analogues. From 2014 to 2017, the number of deaths attributed to synthetic 
1 These are the latest available statistics of annual mortality due to drug overdoses in the United States. The 2018 
statistics are expected to be issued by the Center for Disease Control and Prevention (CDC) in early 2020.
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opioids like fentanyl and its analogues increased 413 percent, and these synthetic opioids are now 
involved in more deaths than any other drug such as prescription opioids, heroin, or cocaine. The 
infectious disease consequences of the opioid epidemic is also of grave concern. Since 2010, the United 
States has seen hepatitis C infection increase more than three-fold. Progress made in HIV resulting 
from injection drug use has stalled.  Moreover, methamphetamine availability and use shows signs 
of renewed growth. According to the most recent available data, 10,333 Americans died in 2017 from 
a drug overdose involving methamphetamine and other psychostimulants with abuse potential, and 
half of these deaths also involved a prescription or illicit opioid, with a quarter involving a synthetic 
opioid such as fentanyl. 
As he has since the beginning of his Administration, the President has marshalled every available 
resource throughout the Federal government to address America’s crisis of drug abuse and addiction2, 
requesting over $34.6 billion in his Fiscal Year 2020 Drug Control Budget to help states, communities, 
and law enforcement respond to the drug crisis and curb drug trafficking through several existing 
and new initiatives. The Trump Administration’s whole-of-government approach reflected in these 
resources and articulated in this Strategy is focused on achieving a singular and overarching purpose: 
to prevent Americans from dying of a drug overdose.
While confronting today’s drug crisis to arrest its growth and reduce its effects, we must also redouble 
our efforts to develop the capability, knowledge, and infrastructure to respond to the evolving nature 
of the drug threat. Over the past year we have seen the drug crisis transform in every dimension. A 
much larger variety of new and highly potent synthetic opioids and other synthetic drugs are being 
rapidly developed and shipped into the United States at an increasing rate. New marketing and sales 
techniques are making their detection and interdiction more challenging than ever. The historically 
low price for some synthetic drugs like methamphetamine is putting them within the economic reach 
of even more potential users, leading to an increasing trend of polydrug use across America. We have 
even seen an evolution in the manner in which drugs are taken into the body, including a startling and 
dangerous increase in concentrated marijuana-type drugs being ingested through vaping devices.  
We must also confront the increasing availability and use of cocaine in the United States. The cultivation 
of coca and production of cocaine in Colombia, the source of the vast majority of the cocaine in the 
U.S. market, remains at record highs even in light of a slight leveling in 2018. Cocaine use in the United 
States continues to rise again after many years of decline.  The National Survey of Drug Use and Health 
(NSDUH) shows that in 2018 there were 1.9 million people aged 12 and above who were past-month 
users of cocaine and 874,000 new cocaine initiates, averaging approximately 2,400 individuals per day. 
Moreover, the suspension of aerial eradication programs in Colombia that began in 2015 led to even 
greater yield from coca plants, resulting in increased production and purity levels that continues to 
bring negative consequences. From 2016 to 2017, overdose deaths in which cocaine was the primary 
2The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) contains descriptions and symptoms of all 
medical disorders classified by the American Psychiatric Association, including substance use disorder.  The 
Strategy and ONDCP uses the word “addiction” to describe compulsive drug seeking despite negative conse-
quences. ONDCP’s use of the term addiction is consistent with the DSM definition of substance use disorder but 
acknowledges that addiction is not a specific diagnosis in the DSM-5.
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contributing drug increased 34 percent. 
The fundamental motivation of drug traffickers remains unchanged. They continue to attempt to secure 
ever-greater profits by expanding their customer base through the introduction of novel substances 
that create new user experiences, reducing production overhead, and mitigating risks to their supply 
chains by continually finding new methods of concealment and routes into the United States. The 
exponential growth in the availability and use of synthetic drugs in the United States continues to 
show us the face of drug use and trafficking for the foreseeable future. Drug trafficking organizations 
can avoid the costly process of harvesting illicit crops and producing plant-based drugs by the much 
cheaper and faster process of chemical synthesis. Potent synthetic drugs are smuggled across our 
borders in small quantities that can be more easily concealed than bulkier plant-based drugs. They 
are also purchased cheaply on the dark web using cryptocurrencies that provide anonymity, and 
shipped into the United States through international mail or as express consignment shipments. The 
combination of low production cost, the anonymity of the dark web and cryptocurrencies, and drugs 
with higher potency than their plant-based counterparts creates a favorable risk-reward structure that 
drug traffickers are now embracing to an even greater degree than ever before.
Given the current drug crisis facing America, and the President’s priorities, this Strategy continues its 
strong bias toward action. The three lines of effort and associated nine goals contained in the Strategy 
were determined by drawing upon the collective expertise at the Federal, State, local and Tribal 
levels by key stakeholders in the governmental, academic, civic, law enforcement, and public health 
communities. Their deep understanding of America’s drug crisis was fundamental to determining 
the Strategy’s nine goals and has allowed us to better understand the complex interplay between the 
availability of drugs in the U.S. market and their use, anticipating changes in the drug environment 
in both the public health and law enforcement domains, and adapting our actions to seize the 
initiative to make lasting progress against this historic challenge. Specifically, Goals 1, 2, 4, 5, and 6, 
which are associated with the line of effort to prevent initiates to drug use, were selected based on 
our consultations with public health experts whose research and clinical experience determined that 
addiction is a disease that must be prevented from the start, and prevention is most effective when it is 
carried out over the long-term with repeated evidenced-based interventions. Similarly, Goals 1 and 3, 
which relate to the treatment and recovery line of effort, were selected based on our consultations with 
public health experts who understand that addiction is a chronic disease that should be treated like any 
other medical condition. This evidence, based on research and clinical expertise of our stakeholders, 
informed our decision to establish these goals. Finally, those goals related to addressing the availability 
of illicit drugs, Goals 1, 7, 8, and 9 were the result of consultations with Federal, State and local and 
Tribal government and law enforcement organizations. These consultations clearly demonstrated that 
almost all illicit drugs are produced outside the United States and then trafficked across the borders 
or via international mail or express consignment carriers. This evidence informed our selection of the 
goals that will aggressively reduce the availability of illicit drugs in American communities.
The global drug trafficking environment is vast, dynamic, and adaptable, but it is not without 
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vulnerabilities. It is only through a unified effort in which the Federal government works with, and 
in support of, creative and resourceful individuals and organizations across the country and within 
the nations of our international partners, that we can address this complex national security, law 
enforcement, and public health problem.
STRATEGIC OUTCOME AND ASSUMPTIONS
This Strategy focuses on achieving one overarching strategic outcome:
Building a stronger, healthier, drug-free society today and in the years to come by 
drastically reducing the number of Americans losing their lives to drug addiction in 
today’s crisis, and preparing now to dominate the drug environment of the future. This 
will be done by preventing initiates to drug use, providing treatment services leading 
to long-term recovery for those suffering from addiction, and aggressively reducing the 
availability of illicit drugs in America’s communities.
This Strategy consists of three interconnected lines of effort designed to achieve the President’s 
strategic outcome of building and fostering a stronger, healthier, and drug-free society: prevention; 
treatment and recovery; and reducing the availability of drugs in America. The single and most 
important criterion of success is saving American lives, and achieving that outcome requires the 
Federal government to work with partners at the State, local, and Tribal levels; the healthcare sector; 
industry; foreign partners; and every concerned American citizen to advance our Nation’s efforts to 
promote and maintain healthy lifestyles, and help build and grow safe communities free from the 
scourge of drug use and addiction.
This Strategy makes several key assumptions:
• Deliberate, sustained, and well-coordinated evidence-based prevention and education 
efforts will, over time, reduce the number of Americans who initiate illicit drug use.
• Better prescribing practices and the promotion of alternatives to prescription drugs that hold 
a high potential for addiction and misuse will have a positive effect on reducing the number 
of initiates to illicit drug use.
• Increasing the availability, access, and quality of evidence-based treatment and recovery 
services for substance use disorder, particularly in rural, tribal and other underserved 
communities, will lead to a greater number of Americans achieving sustained recovery.
• Reducing the availability of illicit drugs in the United States by disrupting the illicit drug 
supply chain will relieve pressure on our public health efforts, allowing our historic effort to 
prevent drug use and increase the availability of treatment to take hold, and increasing the 
potential sustainable success over time.
• Aggressive and versatile drug trafficking organizations will respond to sustained pressure 
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placed upon them by disruption, dismantlement, interdiction efforts, and judicial/
prosecutorial efforts, and will adapt their production and trafficking methods to minimize 
risk and maximize profit.
This Strategy acknowledges several key challenges:
• Drug trafficking and transnational criminal organizations are highly adaptable.
• The path to substance use disorder is multifaceted and extremely individualized. Consequently, 
prevention, treatment, and recovery support services must also be multifaceted and 
individualized to maximize effectiveness.
• Synthetic drugs are easily modified, and rapid modifications in synthetic drug types and 
structures make their early detection a challenge.
STRATEGY IMPLEMENTATION
The three fundamental lines of effort that form the heart of this Strategy—prevention, treatment and 
recovery, and reducing availability—are complementary and mutually supporting. Reducing the size of 
the illicit drug using population involves preventing initiates to illicit drug use through education and 
evidence-based prevention programs. Providing effective treatment services leading to long-term 
recovery for those suffering from substance use disorder, often using medication-assisted treatment 
(MAT) combined with therapy, moves people out of the active user population and puts them on the 
path to recovery. By reducing the number of individuals who use illicit drugs through prevention and 
treatment, we can diminish the market forces pulling illicit drugs across our borders and into our 
communities. Simultaneously, we must drastically reduce the availability of these drugs in the United 
States. Increased availability expands the opportunity for individuals to initiate drug use, and the path 
from first use to chronic use can be brutally short, particularly for potent and highly addictive drugs 
like methamphetamine and opioids. By reducing availability we not only lessen the negative ancillary 
effects of drug trafficking that impact the safety of our communities and the well-being of our citizens, 
we also relieve the pressure on the public health domain in its prevention and treatment efforts.
This Strategy does not enumerate every activity that the Federal government and key stakeholders 
must execute in order to achieve the President’s strategic outcome. Rather, it articulates the President’s 
drug control priorities and sets the strategic direction for the Administration to prevent Americans, 
especially our future generations, from falling into the cycle of drug use and addiction; to provide 
Americans who suffer from substance use disorders with world class treatment and recovery services; 
and to protect America’s citizens from the negative effects of drug trafficking and use. It also provides 
Federal drug control departments and agencies the strategic guidance they need to develop their own 
drug control plans and strategies and ensures programming and resource decisions about Federal 
drug control budget dollars are allocated in a manner consistent with the Administration’s priorities.
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PREVENTION
Preventing drug use before it starts is a fundamental tenet of a comprehensive approach to drug control. 
The science of prevention has evolved and significantly improved, and decades of research show that 
prevention is most effective when it is carried out over the long-term with repeated evidence-based 
interventions. Early detection of those most at risk united with education programs and community 
support mechanisms can alter the trajectory of young people’s lives by increasing protective factors 
while reducing risk factors. Studies show that addiction is a disease that can be prevented and treated 
through sound public health interventions. 
Early recognition and addressing risky substance use can help interrupt the trajectory toward more 
chronic substance use disorders and opportunities to screen for risky behavior should be widespread. 
Many medical organizations have developed evidence-based screening tools and recommend screening 
for drug use and prescription drug misuse for adolescents, as well as adults. All health systems should 
be using screening tools as part of routine health care. Given the high prevalence of co-occurring 
mental and substance use disorders, we must ensure adoption of comprehensive screening and 
integrated treatment for both. There is a significant relationship between mental health and substance 
use disorders at all ages, and it is common for persons to use substances in an attempt to self-medicate 
the symptoms of mental illness. Substance use can mask or exacerbate symptoms of mental illness 
and both disorders share common risk and protective factors that should be assessed and addressed 
together where possible, and treated when indicated. Facilities and professionals serving persons 
with either disorder should have the skill and operational capacity to provide integrated treatment 
that addresses behavioral and physical health, family, and environmental problems in addition to 
substance use. Additionally, treatment providers should recognize the different prevention and 
treatment considerations for children and young adults, and provide age appropriate care. Because the 
developing brain continues growth until at least age 25, children and young adults are more susceptible 
to addiction. Children and young adults also require age appropriate and relevant substance use 
prevention which integrates elements of sociocultural environment, social norms, trauma informed 
approaches, and resiliency-building interventions to help them make healthy lifestyle choices.
Individuals who have experienced a high number of traumatic or challenging experiences in childhood 
are at a significantly elevated risk for developing substance use disorder, and therefore need increased 
access to prevention education and intervention. Adverse Childhood Experiences (ACEs) describes the 
exposure of a person under the age of 18 to trauma, abuse, household challenges and neglect. As the 
number of ACEs increases, the likelihood of engaging in risky health behaviors including alcohol and 
drug use also increases. Research from the National Center for Chronic Disease Prevention and Health 
Promotion has shown that there is a correlation between having a higher ACE score and the number 
of prescriptions or classes of illicit drugs used by an individual, even long after the initial exposure to 
the childhood trauma. While significant challenges early in life, and a high ACE score, do not determine 
that a child will have poor life outcomes, they nonetheless present an increased need for protective 
factors to prevent drug misuse. Young people who are identified as being particularly vulnerable to 
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addiction have an increased potential for positive outcomes if they have access to supportive adults, 
exposure to evaluated drug prevention education, opportunities for academic and extracurricular 
engagement, and clear boundaries related to conduct and drug use.
Evidence continues to demonstrate that combining multiple evidence-based approaches in a 
comprehensive prevention program is more effective than a single activity alone. Moreover, these 
early investments pay large dividends in substantially reducing treatment and criminal justice costs, 
saving taxpayer dollars while reducing the number of young people whose lives are tragically affected 
by early substance misuse.
Finally, while the opioid crisis in America has mobilized awareness, action, and resources to reduce 
overdose fatalities, we cannot ignore the larger landscape of substance use and substance use disorders. 
Poly-substance use has become much more common as individuals make economic decisions about 
the drugs they use. It is important that we take the opportunity to leverage the momentum of our 
national response to the opioid crisis, and apply it to preventing the first use of all drugs using the 
decades of scientific evidence on effective primary prevention to launch and fully support effective 
prevention in homes, schools, the workplace, and communities.
Strengthening the Capacity of State, Local, and Tribal Communities to 
Identify and Prevent Substance Misuse
Family, friends, and local communities are the first line of defense in preventing substance use and 
misuse. In addition, positive adult involvement in children’s lives reduces the likelihood of drug use. 
Given the strong relationship between excessive alcohol use and binge drinking, and the misuse of 
prescription opioids and other illicit drugs, this Strategy emphasizes the need to implement effective 
community-based strategies to reduce misuse of legal substances, along with those to reduce the 
initiation of illicit drug use. Parents and primary caregivers must understand that they can make the 
most significant difference in the child’s attitudes and values regarding the use of drugs. Religious and 
faith-based organizations are also an integral part of the community response to substance misuse, 
and clergy and faith-based organizations have been critical allies at keeping youth away from drugs 
and providing successful support when youth have turned to drug use. This Strategy supports and 
reinforces the positive resources that family, friends, and the community can bring to bear on this crisis 
at both the prevention and the treatment and recovery levels. Parents and families are historically 
under-represented in prevention programs despite the fact that family-based programs play a vital role 
in delaying the onset and use of alcohol and other drugs. This is true for school outreach programs as 
well. Finally, to build effective grassroots solutions, local leaders need greater access to data about drug 
use and drug-related deaths in their communities, as well as information on the demographic factors 
that may be driving those trends. Our rural communities have a particular need for comprehensive 
information about the many Federal funding resources available to combat addiction and to build 
capacity to assist a community in responding to the crisis. Federal grant-making agencies should 
continue to assist these rural communities in knowing what to apply for and the process for applying 
for these resources.
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Enhancing Research and the Development of Evidence-Based 
Prevention Programs
The National Academies of Sciences, Engineering, and Medicine outline three categories of prevention 
intervention: universal, selective, and indicated. Advancing our ability to prevent drug use before it 
starts will require, among other things, more widespread adoption and use of evidence-based methods 
to identify at-risk individuals using strategies that allow for screening, brief intervention, and referral to 
treatment. This is especially important for adolescents and young adults, from the middle school years 
through college age. In addition, we must work with stakeholders to increase opportunities to educate 
and inform child welfare professionals and healthcare providers about the early signs of substance 
misuse and identify resources to support pregnant and parenting women, children of parents with 
substance use disorders or addiction, and children born with neonatal abstinence syndrome (NAS). We 
must engage the research sector and prevention community to build evidence on interventions that 
address the Nation’s ever-changing addiction crisis in diverse communities and conditions.
Continuing to Strengthen ONDCP’s Drug Free Communities Support 
Program
The Office of National Drug Control Policy’s (ONDCP’s) Drug-Free Communities (DFC) Support 
Program, created by the Drug-Free Communities Act of 1997, undergirds the Administration’s focus 
on preventing and reducing youth substance use at the community level. The DFC Program provides 
grants to community coalitions to strengthen the infrastructure among local partners to create and 
sustain a reduction in local youth substance use. Since the DFC Program’s inception, findings from 
evaluations of the DFC Program demonstrate that DFC-funded community coalitions have reduced 
youth substance use. According to the DFC’s 2018 National Cross-Site Evaluation Report, on average 
DFC-funded communities saw significant reductions in middle school and high school aged youth. 
For example, past 30-day alcohol use decreased by 19 percent, past 30-day tobacco use decreased by 
31 percent, past 30-day marijuana use decreased by 7 percent, and past 30-day prescription drug use 
decreased by 24 percent among high school students in DFC-funded communities. The DFC Program, 
through the National Coalition Institute (NCI), will provide training to ensure DFC-funded community 
coalitions have the resources, tools and skillset they need to develop, strengthen, and sustain the 
prevention infrastructure within their communities and among their local partners to effectively 
prevent and reduce youth alcohol, tobacco, marijuana, vaping, and prescription drug misuse. 
Addressing Safe Prescribing Practices
Safe prescribing practices are essential in primary prevention by decreasing the risk of drug addiction 
in patients who take opioids and controlled medications. Safe prescribing is also important for patients 
using medications at high dosages or with central nervous system depressants that in combination 
can lead to drug interactions, including overdose. Finally, safe prescribing also includes prevention of 
using medications for non-medical purposes. 
Significant effort has gone into the development of evidence-based guidelines for the use of 
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medications and non-pharmacological therapies for the treatment of acute or chronic pain. These 
guidelines include recommendations for the dosing and duration of use of opioid analgesics, the use 
of lower risk opioid and non-opioid medications, and the development of innovative pain therapies 
that avoid potentially addictive medications. Another key area of concern is the practice of co-
prescribing opioids and benzodiazepines or other drugs that increase the risk of opioid overdose or 
fatal respiratory depression. Overdose data shows that more than 30 percent of overdoses involving 
opioids also involve benzodiazepines. While opioid and other controlled substance prescribing 
practices continue to improve, continued monitoring, evaluation, and improvement, along with the 
enhanced ability to track prescribing across providers and states through the integration of Prescription 
Drug Monitoring Programs (PDMPs) and Electronic Health Records (EHRs) are essential to promoting 
safe and responsible prescribing, while also assuring appropriate pain care. 
Prescribing naloxone can be life saving for patients on high dose opioids, along with those who use 
illicit drugs or are otherwise at risk for an accidental overdose. In 2018, the CDC reported that only one 
naloxone prescription was dispensed for every 69 high-dose opioid prescriptions, despite the fact that 
the number of naloxone prescriptions has doubled from 2017 to 2018. In 2017, unintentional overdoses 
involving prescribed medications other than illicit fentanyl were more than twice as common as in 
1999. The medical community has responded by limiting opioid prescriptions both in terms of the total 
number of pills prescribed and the total morphine milligram equivalent (MME) of the prescriptions 
dispensed.  The total year-to-date billions of MMEs dispensed as of September 2018 decreased 16 
percent over the prior year.
While we have made significant gains in reducing cases of unsafe or inappropriate prescribing, we 
must remain aware that patients with acute and especially chronic pain and who rely upon opioid 
medications to live comfortable and productive lives legitimately require access to opioid medications. 
Moreover, providers who know and understand their patients are in the best position to administer 
opioid medications at the correct dosage in a safe and responsible manner. Some patients do require 
long term pain management that includes opioids and others may be able to work with their clinicians 
to appropriately taper or discontinue opioid medications. Patients may also require ongoing treatment 
for any co-occurring behavioral health conditions such as depression. In some cases, specialty referral 
to a pain management or substance use disorder specialist may be necessary. While treatment 
guidelines are important and beneficial, the doctor-patient relationship is the foundation of quality 
medical care and must be tailored to meet the individual patient’s needs.
 Expanding the Use of Prescription Drug Monitoring Programs
A PDMP is a proven means to increase accountability in opioid prescribing practices by providing 
information that allows for the coordination of multiple medications, as well as to prevent adverse 
drug interactions. However, PDMP use faces challenges nationwide. In some states PDMP checking 
is optional, and many providers report difficulty using their PDMP because it is not integrated with 
EHRs which interrupts providers’ workflow and creates practical barriers to their use. In those cases 
where states’ integration services are available, the service can be costly. Providers also cite a lack 
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of interstate data-sharing and concerns about patient confidentiality as reasons not to fully use the 
PDMP. Currently, two PDMP data sharing hubs exist and many states share data freely across state 
lines. However, remaining technical, legal, and procedural barriers remain and have thus far prevented 
the full development and execution of a nationwide PDMP capability. Expanding the use of PDMPs is 
a fundamental element of the President’s Initiative to Stop Opioid Abuse, our Strategy, and ensuring 
the safe, legal, and responsible prescribing of opioids for those who need them. Expanding the use of 
PDMPs across the country means each state is choosing the system(s) it wants based on cost, needs, 
or whatever else they determine are important factors; ensuring that all systems communicate with 
each other and are integrated within provider workflows so they can be useful to providers; and the 
creation of a federated group of state PDMPs all able to seamlessly share data needed to connect with 
one another across the country. We will continue to work with our key stakeholders to build on existing 
research regarding barriers to nation-wide PDMP implementation, and drive PDMP integration and 
data sharing, including efforts that address any legal and interoperability challenges. We will also 
pursue incentives for states to make checking PDMPs mandatory for all providers, such as the Centers 
for Medicare and Medicaid Services’ new incentive that offers five bonus points to prescribers who 
query the PDMP under the Medicare Merit Based Incentive Payment System.
Expanding Drug Take-Back across the Country
The Drug Enforcement Administration’s (DEA) twice-yearly Take-Back Day serves as an opportunity for 
citizens to dispose of unused and unneeded prescription drugs and a chance to support community 
drug prevention efforts. This past year, amidst an outbreak of vaping-related lung illness, the DEA 
has included the Take-Back of vaping products in addition to unused prescriptions for the first time. 
Although year-round take-back programs are expanding, including some by retail drug stores, the 
DEA program remains an important element to raise public awareness about the need to reduce 
unused medications available for potential diversion and misuse. Expanding the number of registered 
collectors, including hospitals and law enforcement centers, would allow states and municipalities to 
reduce their reliance on the Federal government for collection, disposal, and transportation. It should 
be noted that the number of authorized collectors has climbed from almost 6,000 in January 2019 to 
over 8,850 in December 2019, an increase of 40 percent.  The DEA and other Federal partners should 
work to engage State, local, and Tribal governments to raise awareness of the importance of disposing 
unused medications, expand the number of permanent disposal sites across the country, and increase 
the opportunity for their citizens to do so safely and easily. In addition, at-home disposal options 
should be more widely available, particularly in rural and tribal communities where prescribing rates 
are historically high, take-back options are limited, and transportation may be a barrier to accessing 
existing disposal locations.
Conclusion
Decades of research and data demonstrate addiction is a preventable disease. Today, we continue 
to face a compelling need to invest in a comprehensive approach to preventing drug misuse that 
emphasizes concrete and lasting policy change at the Federal, State, Tribal, and community levels. 
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The Administration will continue to focus its efforts and work across the government to empower 
communities, youth, parents, caregivers, and families to come together to create sustainable programs, 
policies, and practices to combat drug abuse. We know that every dollar we invest in evidence-based 
substance use prevention programs has the potential to save much more in health care and criminal 
justice system costs and enhance the overall quality of life for communities and their citizens.
TREATMENT AND RECOVERY
Addiction is a chronic medical condition that affects the brain by causing distinct cognitive, behavioral, 
and physiological changes. There is a need to improve the availability of treatment while concurrently 
enhancing the quality of that treatment. Research shows that treatment is most effective when it 
addresses addiction as a chronic condition requiring continuing services and support structures over 
an extended period of time. This can include ongoing outpatient services including MAT programs, 
intensive initial services such as detoxification, hospitalizations, and residential treatment, followed by 
continued care and recovery support in the community. Expanding treatment availability also requires 
accessibility for older adults and people with disabilities, including ensuring treatment centers are 
physically accessible. Every individual needs an assessment and individualized treatment plan to 
address their needs as they relate to opioid and other substance use disorders.
Unfortunately, most people who need treatment do not seek it. According to the NSDUH, in 2018 an 
estimated 21.2 million Americans aged 12 or older needed treatment for a substance use disorder, 
but only 3.7 million received any kind of treatment and only 2.4 million received that treatment at a 
specialty facility—a disparity known as the “treatment gap.” In some cases treatment capacity is simply 
not available, and in others people do not fully acknowledge their need for treatment. Therefore, in 
addition to expanding treatment capacity, we need to engage with those people who need treatment 
but, for whatever reason, are not seeking it. Furthermore, according to the 2018 NSDUH, 62 percent 
of the 7.4 million working age adults who had illicit substance use disorder were employed either full-
time (45 percent) or part-time (17 percent). The perception that one must “hit rock bottom” to need 
treatment is not accurate, and we must work to raise awareness of early intervention.
As a Nation, we must encourage people who need treatment to seek it, create greater access to 
treatment, and ensure there is adequate capacity and quality to accommodate the need. The 
Administration prioritizes several distinct initiatives to achieve these goals. First, we must expand 
a proactive response to overdoses to ensure that the patient can enter into a treatment program 
designed to meet his or her individual needs. Second, we need to use evidence-based approaches to 
treatment and make MAT the standard of care for opioid addiction. This means increasing the number 
of physicians providing high-quality, evidence-based MAT for opioid use disorders and increasing 
the availability of MAT for incarcerated individuals and people living in rural and tribal communities. 
Expanding treatment infrastructure will enable us to increase the initial treatment for the vast majority 
of people who require treatment but are unable or unwilling to obtain it. Third, we need to ensure 
that health insurance plans provide substance use disorder benefits in parity with medical/surgical 
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benefits and implement the SUPPORT Act which reduces reimbursement barriers, to encourage 
people who need treatment to make the positive decision to pursue it. Finally, the use of drug courts 
and diversion programs will foster entrance into treatment programs, steering people away from the 
cycle of destructive and self-defeating behaviors that is the hallmark of the disease of addiction. 
People in long-term recovery demonstrate that recovery is possible and share the message that 
addiction is a disease and not the result of a personal or family failing. In doing so, they help lift 
the stigma, misunderstanding, and shame that prevent too many Americans from seeking help for 
substance use disorders. Often, these factors can close off opportunities for those in recovery who seek 
to become healthy and fully rejoin and contribute to their communities. Implementation of recovery-
supportive and drug-free workplace policies is another important component to improve both the 
health of individuals and communities, as well as economic outcomes for affected workers. The 
Administration recognizes the toll that misunderstandings and stigma can take on people, families, 
and communities struggling with addiction, and is taking steps to address them. 
Addressing these and other challenges will require a comprehensive multi-year strategy to educate 
the public and policymakers, reduce stigma and misunderstanding of addiction, better integrate 
substance misuse screening and treatment into mainstream health care, build and stabilize the 
addiction treatment workforce, increase access to treatment, and foster more effective approaches to 
care for people with substance use disorders.
PROVIDING TREATMENT
Improving the Response to and Monitoring of Overdose
Naloxone is an opioid antagonist medication that can rapidly reverse an opioid overdose. However, 
access to naloxone varies throughout the country. Most states have protocols to expand access to 
naloxone, such as allowing pharmacists to dispense naloxone under a standing physician’s order. The 
U.S. Food and Drug Administration (FDA) is working to facilitate the development of nonprescription 
naloxone by creating and testing appropriate consumer-friendly Drug Facts labels. However, even 
simple rescue breathing can keep a person alive until the naloxone arrives and can be administered. 
We will begin to increase public awareness of the importance of rescue breathing as a critical life-saving 
measure in the event of an opioid overdose when naloxone is not immediately available. Moreover, we 
must do more to ensure that the reversal of a potentially fatal overdose is not just another event in a 
long and protracted struggle with an addiction to dangerous drugs, but rather the first important step 
toward effective treatment and sustained recovery.
Enhancing Evidence-Based Addiction Treatment
Treatment models that demonstrate the best outcomes incorporate behavioral, psychosocial, and 
pharmacological elements, and are tailored to the specific circumstance of the individual. The ability 
to provide evidence-based treatment for those who need it depends on skilled and well-trained 
providers who are appropriately credentialed and licensed. This must include a complete assessment 
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for substance use disorders by a qualified medical professional; access to addiction treatment such 
as MAT as a deliberate choice made by a qualified professional in consultation with the patient for 
a substance use disorder; access to relevant psychosocial treatments such as therapy and relapse 
prevention; and, the treatment of co-occurring medical and mental health disorders. We must help 
health providers reduce and treat incidents of NAS by promoting responsible drug prescribing for 
pregnant women, promoting uniform screening and diagnostic tools, and providing women and their 
babies with evidence-backed pre- and postnatal treatment. Health providers and other stakeholders 
should also promote effective gender-relevant models for substance use disorder treatment for 
pregnant and parenting women. Children and young adults have unique prevention and treatment 
considerations, and the treatment gap for youth and young adults ages 12-17 is greater than the general 
public. We need a concerted effort to engage clinicians, school staff, employers, families, caregivers, 
juvenile justice professionals, community leaders, and health plans and issuers to ensure youth 
receive treatment that is developmentally appropriate, readily available, and adequately covered by 
insurance plans. 
Eliminating Barriers to Treatment Availability
Individuals with substance use disorders, including opioid addiction, should have access to evidence-
based treatment. According to the Bureau of Justice Statistics and the Substance Abuse and Mental 
Health Services Administration (SAMHSA), this is particularly true for people in the criminal justice 
system where nearly 60 percent of people in state prisons and two-thirds of people in jail met the 
criteria for drug dependence or misuse. Fewer than half of the privately funded substance use disorder 
treatment facilities offer MAT, and only a third of patients with opioid use disorders have access to those 
treatments. This is especially true in rural areas where the compelling need for access to treatment far 
exceeds its availability. The Administration will work across the Federal government to remove barriers 
to substance use disorder treatments, including those obstacles to FDA-approved MAT, counseling, 
certain inpatient/residential treatment, and other treatment modalities. All primary care providers 
employed by the Federal government should screen for alcohol and drug use disorders and, if the 
patient requests it, provide substance use treatment or a referral for such treatment.
Leveraging Drug Courts and Diversion Programs
Providing individuals arrested for non-violent drug-related offenses the opportunity to participate in 
a drug court program or outpatient treatment while under supervision is increasingly becoming the 
practice throughout the country. From 2009 to 2014 the number of drug courts in the United States 
increased by 24 percent, reaching 3,057, and today there are more than 3,100 drug courts across the 
United States, half of which are adult treatment drug courts according to the Department of Justice. 
Recently, some pioneering police departments began diverting individuals addicted to drugs directly 
to treatment in lieu of arrest. Many communities are adopting pre-arrest diversion programs where 
individuals with a substance use disorder are offered treatment in lieu of arrest and deflection models, 
where those struggling with addiction can walk into a participating police station 24 hours a day for 
police-assisted rapid treatment entry. The Administration supports these innovative programs and will 
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continue support for State, Tribal, and local drug courts to provide offenders struggling with addiction 
access to evidence-based treatment as an alternative to or in conjunction with incarceration, or as a 
condition of supervised release.
Building the Addiction Treatment Workforce 
Additional efforts must be made to build an addiction medicine infrastructure and expand the 
addiction profession and peer recovery support services workforces. Medical providers and patients 
may not have access to a network of treatment and recovery providers and services, and the actual 
availability of services when needed continues to be a challenge. Federal partners, medical institutions 
and educational systems must improve recruitment efforts to build and broaden addiction medicine 
expertise. The entire medical community is encouraged to engage in expanding addiction medicine 
knowledge. The current climate requires expansion of addiction medicine specialists in psychiatry and 
general medicine. Beyond the addiction medicine experts, all medical specialists are encouraged to 
learn about the treatment of addiction. The addiction treatment workforce covers a broad spectrum 
of professionals from peer counselors and peer support specialists, to addiction counselors, social 
workers, nurses, nurse providers, physician assistants, psychiatrists, and physicians of all specialties. 
We will work to grow and enhance all levels of the professional, mid-level and paraprofessional 
addiction workforces. 
Improving Efficiency in Surveillance and Infrastructure 
Current public health infrastructure and its monitoring systems must improve to enable real-time 
information and epidemiological surveillance. Efforts must be made to understand infrastructure 
and monitoring capabilities to improve existing systems. Modernizing public health data systems 
includes having a trained workforce that can manage modernized systems and develop and improve 
the criteria and indicators necessary for identifying new or evolving classes of illicit drugs. A part of 
this process is to examine the capabilities and capacities around local toxicology testing, including 
the recommended minimum detection levels for screening and confirmatory testing of drugs, the role 
of coroners and medical examiners, and how issues with infrastructure impact data collection. The 
Federal government, in collaboration with States and localities, should explore ways to better measure 
and track treatment services and recovery housing availability against demand and need on the local, 
state, and national levels. 
SUPPORTING RECOVERY
Utilizing Recovery Support Organizations
The sense of community and the establishment of a safe place to live are essential ingredients for 
all people who are breaking the grip of addiction and making the journey of recovery. Healthcare 
professionals, substance use disorder treatment providers, and government agencies need to utilize 
persons in recovery as a resource. People with lived experience offer an intimate understanding of 
the nature of addiction, the negative feelings associated with this disease, challenges to be met, and 
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whose very presence exemplifies hope for a new life to those still suffering. 
Recovery-oriented services include Peer Recovery Support Services (PRSS), Recovery Community 
Organizations (RCOs), Collegiate Recovery Programs (CRPs) and other supportive community-based 
organizations. In rural areas where distance to service is a challenge, these recovery support services can 
be provided through mobile or teleservices. Peer Recovery Support Services provide essential services 
including help with navigating difficult social and family relationships, and offering employment-
related advice. These PRSSs often provide a bridge to other communal support systems (mutual aid, 
faith groups, alcohol and drug-free social and recreational activities) and to other more formal systems 
such as child welfare offices, healthcare providers, treatment professionals, housing assistance 
programs, and job training. Recovery Community Organizations provide recovery-oriented education, 
community outreach, and peer-based recovery services among other invaluable contributions.
To further increase the development of RCOs and enhance their valuable services, Federal agencies 
should consider uniform standards for recovery support services. These PRSS standards will seek to 
augment care similar to SAMHSA’s Recovery House Guidelines, the National Association of Recovery 
Residence’s (NARR) standards, the Association of Recovery Organizations (ARCO), the Council on 
Accreditation of Peer Recovery Support Services (CAPRSS), the Oxford House, and other professional 
organizations with a mission to improve the quality of recovery support services. 
Furthermore, while the number of CRPs on the campuses of large public universities, private higher 
education institutions, and community colleges has increased rapidly over the past decade, they are 
still the exception rather than the rule. Every higher education campus in America could potentially 
benefit from some type of CRP. Adolescent recovery support services are especially scarce and of 
tremendous value to youth, given the importance of peer networks to their social development. 
Recovery high schools and alternative peer group models hold great promise for meeting the needs 
of youth, either in active recovery or in encouraging youth to seek it, and we must encourage their 
increased use across the Nation. 
For many individuals seeking recovery, a safe, drug and alcohol-free living environment that encourages 
recovery is vital to their growth and development. Access to quality recovery housing helps people 
overcome the challenges associated with substance use disorders. 
Improving Opportunities for Employment for Those in Recovery
Americans in stable recovery from addiction deserve fair consideration for any job for which they are 
qualified. Today, millions of Americans from all walks of life are in recovery. Many of these individuals 
have barriers to employment, such as past misdemeanor or felony drug-related criminal convictions 
that can impede or prevent them from securing employment for which they are fully qualified. In 
addition to the obstacles created by a past criminal conviction, those in recovery can face additional 
hardship in finding employment as a result of laws that prohibit the hiring of individuals with a past 
conviction. These legal restrictions can create additional difficulties for those seeking to fully rejoin the 
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community and sustain a life in recovery. The Administration will work across the Federal government 
and the private sector to increase hiring opportunities for those in recovery, including for those with 
past criminal convictions. This will include providing the best information to employers on the overall 
benefits of bringing these individuals back into our workforce, developing best practices to increase 
their employment prospects, and increasing the availability of workforce training, transportation, and 
safe housing that enables those in recovery to take their place in the American workforce.
Expanding the Scientific Understanding of Peer Recovery Support 
Services
While much is known about the process of addiction and about interventions to help address it, less 
is known about the recovery process and its various trajectories, components, and stages. A better 
understanding of the recovery process will help in the design and targeting of both clinical and recovery 
support service interventions that are stage- and trajectory-specific. Continued research is needed to 
design and target clinical and recovery support interventions and strategies for long-term recovery. 
However, while the positive anecdotal evidence of the near-term effectiveness of recovery support 
service models is strong, empirical and rigorous research is required on their long-term effectiveness, 
the characteristics of those who benefit most from them, and peer recovery support services’ role 
within and impact on broader systems and communities.
Even though evidence suggests that recovery support service models are efficacious in lessening the 
consequences associated with active addiction, more rigorous research is required to develop a deeper 
and broader understanding of how these services can best be utilized to mitigate relapses, save lives, 
and reach a segment of the population who are in need of services. To date much is known about the 
process of addiction, including specific interventions and treatment models, but less is known about 
the recovery process and its various trajectories, components, and stages. A better understanding of 
the recovery process will help practitioners design interventions that can be more effective in meeting 
people in all stages of active use and recovery. In other words, more research is needed to design and 
target clinical and recovery support interventions to assist all people in achieving long-term recovery.
Reducing Stigma and Making Recovery Possible
Americans in recovery are a vital part of every community in the United States, and they seek the same 
things other Americans want and need—a good job, a safe place to live, a strong social support network, 
such as a faith community, and the companionship of neighbors and friends. Many people who go 
through recovery lack a supportive network and the necessary resources to be successful such as safe 
housing, transportation, or childcare. These hurdles can impede employment and healing, which 
can lead to potential relapse. For long-term recovery to work we must create mutually-supportive 
communities where individuals improve their physical, mental, spiritual, and social well-being and 
gain skills and resources to sustain their recovery. The millions of Americans in long-term recovery 
from addiction demonstrate that recovery is possible, and they share the message that while addiction 
is a chronic disease, it can be effectively addressed with evidence-based treatment. By sharing their 
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stories, individuals in recovery help lift the stigma, misunderstanding, and shame that prevent too 
many Americans from seeking help for substance use disorders. While stigma knows no geographical 
boundaries, this can be a particular challenge in rural and tribal communities that are often closely 
knit. By promoting, supporting, and celebrating recovery, we can reduce stigma and offer hope and 
encouragement to those struggling with addiction. Many people in recovery have also dedicated their 
lives to helping others affected by substance misuse as recovery coaches and counselors, a critically 
important and growing component of the addiction service workforce. The Administration will continue 
in its efforts to better educate the public, healthcare professionals, and policymakers on the science of 
addiction and the promise of recovery, and how stigma, poor language choice, and misunderstanding 
can undermine efforts to reduce drug use and its consequences.
Conclusion
Untreated substance use disorder can result in violence, crime, and risky behavior that jeopardizes 
the health and safety of individuals, families, and communities. The moment a person is ready and 
willing to enter treatment can be fleeting and infrequent. In addition to matching the individual with 
the most appropriate care model, efforts to expand treatment must include the capability to act 
quickly on the demand for treatment whenever and wherever the opportunity is presented. Anytime 
someone seeking help for addiction calls a treatment center, doctor’s office, hospital, health clinic, or 
other medical facility, that person should immediately be referred to some level of assistance. Even if 
a treatment slot is not immediately available, recovery coaches, peer counseling groups, and families 
who have learned about addiction can provide help until the right treatment opportunity becomes 
available. It is in everyone’s best interest—affected individuals, their families, and the Nation—for 
high-quality, evidence-based drug treatment to become more easily accessible. The current opioid 
crisis highlights the urgent need to encourage those who need treatment to seek it, rapidly increase 
treatment admissions for opioid addiction, improve treatment retention, and increase the number of 
individuals who successfully achieve sustained recovery. It is also essential to eliminate the stigma, 
misunderstanding, and legal and regulatory barriers that delay or prevent treatment access and 
impede recovery. In addition to saving lives and helping people in recovery achieve their full potential, 
these changes will help ensure that the significant public investment in treatment pays off in terms of 
long-term recovery.
REDUCING THE AVAILABILITY OF 
ILLICIT DRUGS IN THE UNITED STATES
Almost all of the illicit drugs causing American deaths are produced outside the United States and 
trafficked across the Nation’s borders and through the international mail and express consignment 
carriers. Large and established Drug Trafficking Organizations (DTOs), the Transnational Criminal 
Organizations (TCOs) responsible for producing and shipping the drugs into the United States, threaten 
the health and safety of our communities by exposing our citizens to substances such as illicit fentanyl, 
non-fentanyl synthetic opioids, heroin, cocaine, and methamphetamine, which kill tens of thousands 
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of Americans each year. The increased use of illicit drugs burdens the U.S. health care system and leads 
to lost productivity and civil engagement. Moreover, drug trafficking sustains a vast domestic and 
international criminal enterprise that enables corruption, undermines governance, has a destabilizing 
effect on our partner nations, and funds a range of illicit activities. Law enforcement agencies at all 
levels—Federal, state, local, and tribal—have achieved considerable success in combating drug 
trafficking and use, yet traffickers continue to refine their methods and adopt new techniques for 
delivering potent illicit drugs to our communities. Responding to the aggressive trafficking and 
distribution techniques of DTOs is an urgent national security and law enforcement priority.
The non-medical use of prescription drugs presents another dimension of the availability problem. 
Many active drug users report obtaining prescription drugs from friends, family members, and in some 
cases, healthcare providers. The overprescribing of prescription drugs, the diversion of prescription 
drugs for non-medical use, and the lack of accountability or oversight in prescribing practices increase 
the availability of prescription drugs in America’s homes and workplaces, making it far too easy 
for them to fall into the wrong hands. Moreover, drug dealers exploit the demand for prescription 
medicines and traffic in counterfeit pills containing illicit fentanyl, or one of its analogues. These 
drugs are difficult to distinguish from legitimate prescription medicines, and because they are most 
often milled and pressed in variable formulations in clandestine locations, it increases the chance for 
accidental overdose.
Disrupting, Dismantling, and Defeating Drug Traffickers and Their 
Supply Chains
While DTOs often are involved in poly-drug trafficking and other criminal activity, the unprecedented 
rise in deaths from the opioid crisis demands that we prioritize U.S. government efforts on the 
individuals and groups involved in the smuggling and sale of the most deadly drugs such as synthetic 
opioids and heroin. As these organizations continue to modify their techniques and operations in 
an attempt to reduce risk and maximize profit, we must anticipate and then respond to changes in 
the drug trafficking environment, identify and exploit vulnerabilities in the illicit drug supply chain, 
and seize the initiative from drug traffickers in order to disrupt their activities and dismantle the 
infrastructure they use to sustain their illicit enterprise. Along with aggressive actions to prevent the 
further expansion of these criminal enterprises in our country, we must also work with foreign partners 
to attack criminal networks, principally those in the Western Hemisphere, whose drug trafficking and 
associated criminality directly impact migration and border security issues affecting the United States.
Working with International Partners
The U.S. Government will focus its diplomatic efforts to encourage partner nations to produce results 
that match the growing threat from illicit drugs. Consistent with the National Security Strategy, we 
will prioritize assistance with partners who are aligned with U.S. interests, are showing results, and 
building the capacity to address these threats independent of U.S. assistance programs. This will 
require partners’ renewed commitment to disrupt the illicit supply chain through the interdiction and 
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seizure of the illicit drug supply, illicit funds, and weapons; eradicate poppy and coca plants; find and 
dismantle the labs used for all illicit drug processing; develop and sustain robust law enforcement 
and justice systems; maintain the rule of law and ferret out corruption; and arrest and prosecute drug 
traffickers operating within their own land borders, territorial waters, and airspace. These efforts are 
not only important in their own right but will complement, and be informed by, a strong domestic 
public health response to the crisis aimed at reducing the use of these drugs in the United States. 
We will continue to work bilaterally with the primary drug producing and trafficking countries most 
affecting the United States, emphasizing our shared responsibility for today’s drug problems and the 
strong desire for tangible progress in the years to come. Regional relationships will be an important part 
of our international approach, allowing us to share information and harmonize our drug policies in the 
face of a constantly changing threat. Moreover, we will take full advantage of the strong multilateral 
framework that exists to address the global drug problem, particularly in terms of supporting the three 
international drug control conventions and providing leadership in the processes for internationally 
scheduling, controlling, and monitoring illicit drugs and their precursor chemicals.
Combating Illicit Internet Drug Sales
Over the past three years, illicit drug sales on both the clear and the dark web have further expanded the 
illicit drug market, allowing individuals to purchase dangerous drugs directly from their manufacturers 
or individual intermediaries instead of through established trafficking organizations, and have 
them shipped directly to their homes. We must continue to disrupt the ability of drug traffickers to 
exploit the anonymity, distance, and financial transaction reliability provided through internet sales 
by degrading the implicit trust between buyer and seller required for illicit on-line transactions. We 
must use existing authorities to their maximum effect to target drug traffickers and their enablers 
by employing both passive and active measures to disrupt and exploit illicit drug related activities 
operating on both clear and dark webs. Contesting drug marketplaces in the cyber domain and 
disrupting the use of cryptocurrencies for illicit drug sales requires a coordinated and well-resourced 
framework of relationships, laws and regulations, procedures, and capabilities. This will allow us to 
identify and target the network of actors involved, and prosecute those who use the open or dark 
webs to market, sell, and purchase illicit drugs. Utilizing our full range of authorities and cyberspace 
capabilities in a sustained effort against the internet drug market, will erode this implicit trust and 
disrupt illicit operations on the clear and dark webs over time.
Focusing Federal Government Effort against Illicit Drug Delivery 
through the Mail and Express Consignment Networks
We must complement our efforts against internet drug sales with a sustained effort to disrupt the flow 
of illicit drugs shipped through the international mail and express consignment environments. This 
requires maximizing the policy and regulations, international relationships, facility infrastructure, 
and technology required to aggressively target, detect, and intercept illicit drugs transported through 
the international mail and express consignment environments both internationally and domestically. 
We must work with our international partners to develop the ability to share Advance Electronic Data 
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for all international shipments, in accordance with the President’s Initiative to Stop Opioid Abuse, and 
continuously refine targeting algorithms to identify and interdict international shipments before they 
depart the source country and at U.S. Ports of Entry. We must help critical partner countries develop 
the ability to detect and intercept illicit drugs in their domestic mail and express consignment systems 
before those drugs depart for the United States and enter the U.S. mail or commercial carrier system. 
We must continue our extensive work with private sector partners which is critical to disrupting the 
manufacturing, marketing, sale, and shipment of drugs through the nation’s commercial infrastructure. 
Finally, we must develop next generation technology and screening capabilities to increase our ability 
to detect illicit drugs once they enter the mail and express consignment systems within the country, 
and improve testing capability to determine the precise type and source of illicit drugs seized. This 
investment in science, technology, resources, and international relationships is necessary to determine 
the type, source region, production location, and route traveled for all illicit drugs seized by the United 
States and its international partners.
Interdicting the Flow of Drugs across the Physical Borders and into the 
United States
Along with the challenge of drug trafficking via internet sales and mail and express consignment 
delivery, drugs continue to flow across our land borders and through the maritime and air routes. 
Stopping these flows must continue to be a part of our comprehensive interdiction efforts. This work 
includes enhancing the border’s physical security infrastructure, especially along our southern border. 
The historically high levels of cocaine production in Colombia, along with heroin, methamphetamine, 
and illicit fentanyl production in Mexico, combined with the vast number of routes and conveyances 
into the United States, make the challenge of combating drug trafficking across our physical borders 
no less daunting than it has been for the past several decades. Federal agencies should expand efforts 
in the detection and monitoring of the air and maritime approaches to the United States; the detection 
of illicit drugs and precursor chemicals shipped in commercial containers; and interdiction of plant-
based drugs such as heroin, cocaine, and marijuana, as well as synthetic drugs and their precursor 
chemicals, along the Nation’s land borders. Moreover, increasing cooperation and effort from foreign 
partners who can contribute vital information on trafficking patterns and assets to seize drugs bound 
for the United States, will complement U.S. efforts.
Disrupting and Dismantling the Illicit Drug Production Infrastructure
The United States and Mexico have expanded cooperation to address the common threat of illicit 
opioids, and both governments agree that reducing the supply of heroin, methamphetamine, and 
illicit fentanyl is a shared responsibility. Mexico has increased its efforts to eradicate poppy fields more 
effectively, destroy clandestine laboratories, and interdict heroin and other drugs before they reach 
the U.S. border. The U.S. Government’s partnership with Mexican law enforcement officers, analysts, 
chemists, and military personnel to identify and safely dismantle clandestine drug laboratories that 
produce heroin, methamphetamine, and illicit fentanyl has increased Mexico’s capability in addressing 
the dangers synthetic drugs present to law enforcement.  
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We must work with partners to address expanding coca cultivation and cocaine production in 
Colombia and the broader Andean region in a comprehensive manner. Key elements of cooperation 
with proven partners such as Colombia and Peru include increasing all forms of illicit crop eradication, 
alternative development and economic opportunities, interdiction, investigation and prosecution, 
judicial support, and public health cooperation, all of which must be long-term and sustainable. Since 
coca fields differ in their level of productivity, this approach will be most successful if we focus in areas 
of high-yield coca cultivation. Unfortunately, these areas generally have limited government services 
and lingering security concerns, and will require concerted effort over several years to turn the rising 
tide of cocaine production.
Within the United States, marijuana cultivation on public lands, and within National Forest System 
lands in particular, is a significant issue. Cultivation activities not only sustain the illicit marijuana 
trade but also produce large volumes of hazardous materials that pose a significant risk to the public 
and the environment. Wildlife, soil, and vegetation are often contaminated by the various hazardous 
substances involved in the cultivation process. Personnel conducting enforcement, cleanup, and 
regulatory activities, as well as the public, are at considerable health risk from exposure to these 
chemicals. Continued firm action is required against the exploitation of the Nation’s public lands 
through increased detection, disruption, reclamation, and prosecutions.
The majority of illicit synthetic drugs available in the United States are manufactured abroad. New illicit 
synthetic drugs and the precursor chemicals used to make them originate predominantly in China, 
although most of the methamphetamine available in the United States is manufactured in Mexico 
and the rising production of illicit fentanyl in Mexico has become an increasing concern. Increased 
collaboration with Mexico, China, and other partners on shared drug priorities can help disrupt drug 
trafficking networks, along with the corrupt or compromised systems that support them, and reduce 
the availability of dangerous synthetic drugs in the United States. The United States will continue 
bilateral exchanges with China, Mexico, Colombia, and other source and transit countries to reduce 
production and trafficking of synthetic drugs destined for markets in the United States and support 
collaboration with international partners impacted by drugs from the very same sources.
Leveraging the Full Capabilities of Multi-Agency, Multi-Jurisdictional 
Task Force Programs
Transnational drug trafficking organizations, by definition, operate across national, state, and local 
boundaries to produce, transport, and distribute dangerous and addictive drugs. In order to protect 
their criminal enterprise, drug trafficking organizations also commit violent crimes, threaten and 
corrupt public officials, traffic weapons, and launder their criminal proceeds. Accordingly, no single 
government, or government organization, alone can defeat these threats. Our best strategy to 
dismantle and disrupt criminal organizations is to employ the coordinated efforts of multi-agency, 
multi-jurisdiction task forces. Such task forces are best organized to work with international partners 
and to take coordinated action on shared investigative information and intelligence. 
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ONDCP oversees the High Intensity Drug Trafficking Areas (HIDTA) Program which provides assistance 
to law enforcement agencies operating in areas determined to be critical drug-trafficking regions of 
the United States. HIDTAs provide an umbrella to coordinate Federal, state, local, and tribal drug law 
enforcement agencies’ investigations, and act as neutral centers to manage, de-conflict, analyze, 
provide intelligence support to, and execute drug enforcement activities in their respective regions. 
With the last year’s inclusion of Alaska, the first new HIDTA in 17 years, the 29 regional HIDTAs now 
include designated areas in all 50 states, Puerto Rico, the U.S. Virgin Islands, and the District of Columbia. 
The regional HIDTAs bring together more than 21,000 Federal, state, local, and tribal personnel from 
500 agencies through 800 enforcement, intelligence, and training initiatives, all designed to disrupt 
illicit drug trafficking and dismantle criminal and drug trafficking organizations. The Administration 
will ensure strong support for counterdrug enforcement, including by supporting Federal participation 
in multi-jurisdictional task forces and enhancing support for information sharing at all levels. This will 
ensure that national data systems receive input from state, local, and tribal agencies, and that these 
agencies, in turn, have access to data compiled by Federal agencies that can prove vital to their own 
investigations.
Interrupting the Financial Activities of Drug Traffickers
Illicit drugs enter the United States from global suppliers as the result of a long and complex process 
involving manufacture, concealment, movement, purchase, and delivery. The illicit drugs may change 
hands several times during the process, and this often necessitates the transfer of money, either as 
payment for services or for delivery of the final product. Traditionally, street-level sales of illegal drugs 
are conducted with cash, creating immediately liquid assets that are almost impossible to track. As 
technology and money laundering methods have adapted over the years to circumvent Anti-Money 
Laundering regulations, drug traffickers have initiated many new techniques to enable the traditional 
method of hard currency transactions. Although some of these methods create additional investigative 
evidence, emerging technologies continue to outpace banking regulations and consistently provide 
drug traffickers the means to launder large amounts of their illicit proceeds.
Most of the revenue generated from illegal drug sales in the United States is maintained at the retail 
level of drug distribution. However, illicit proceeds that flow back to international sources of drug 
supply are most often used to finance other illegal activities or the next cycle of illegal drugs flowing 
into our communities, posing a continual threat to the country. These funds also corrupt and weaken 
the government infrastructure of source and transit countries, limiting those governments’ ability to 
combat TCOs, escalating violence, and threatening the stability of the governments we partner with to 
counter illicit activity. We will combat this threat and target the drug proceeds that motivate criminal 
activity by attacking TCOs’ financial capital; preventing the circulation, transfer, and concealment of 
their illicit proceeds; and, ultimately decreasing their wealth and their incentive to function.
Enhancing Law Enforcement Capacity
Success in reducing the availability of illicit drugs in our country requires continuing to strengthen 
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the capacity and tools to fully understand, and relentlessly respond to, the increased drug threat 
we face. As our National Security Strategy states, this capacity building includes national-level 
strategic intelligence and planning capabilities to improve the ability of departments and agencies 
to work together to combat TCOs, particularly those who traffic drugs at home and abroad. We must 
improve our capability to dismantle TCOs as a whole through greater coordination and focus, directly 
benefiting our counterdrug efforts. Improved strategic planning must be informed by better strategic 
intelligence on transnational organized crime and global criminal networks, fusing law enforcement 
and Intelligence Community information and intelligence to create the most complete picture 
available of criminal networks. We must use that information to identify and exploit vulnerabilities 
in drug trafficking networks, using the full range of law enforcement capabilities including criminal 
prosecutions, financial disruption tools such as asset forfeiture proceedings, and security operations 
to remove the profits from crime. Moreover, we must maintain pressure on these organizations over 
time and prevent them from regenerating their capabilities. We must also emphasize both actions 
that lead to prosecutions—to reduce networks’ ability to operate, through the investigation, arrest, 
and prosecution of critical personnel —and those that lead to the long-term disruption of network 
operations such as the seizures of illicit drugs, precursor chemicals, illicit funds, and weapons.
Our conventional focus on targeting high-level individuals within the hierarchy of well-organized and 
sophisticated DTOs must evolve toward identifying and targeting vulnerable critical components of more 
fluid and dynamic organizations such as financial facilitators, corrupt officials, and key transporters, 
to affect a significant disruption of DTO activities, targeting key nodes to attack the entire network 
through its enablers. Degrading and defeating criminal networks that have become more resilient 
because they are decentralized, redundant in capabilities and capacities, and compartmentalized, 
requires identifying the key nodes enabling DTO operations and simultaneously targeting them for 
maximum effectiveness over time. Agile interagency and international coordination will allow for 
better detection of changes in the trafficking supply chain, which will support intelligence-driven 
operations against identified vulnerabilities, from drug production to delivery to the end user.
Conclusion
The increased availability and use of illicit drugs is taking far too many American lives and destroying 
American families. It burdens the U.S. health care system and leads to lost productivity and civil 
engagement here at home, and global drug trafficking sustains a vast domestic and international 
criminal enterprise that enables corruption and destabilizes partner nations abroad. America’s drug 
crisis has created a complex national security, law enforcement, and public health challenge for the 
Nation, and this challenge will remain with us for the foreseeable future. We must leverage the full 
capabilities of the U.S. intelligence and law enforcement communities, our military, domestic law 
enforcement and criminal justice capabilities, and sustained engagements with the governments of key 
partner nations and international organizations to stop the flow of these drugs across our borders and 
into our communities, and use that capability to posture ourselves for an ever-evolving drug trafficking 
environment. Our actions will continue disrupting the evolving illicit supply chain, decreasing the 
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volume of drugs being sold over the internet; decreasing the cultivation of illicit crops like poppy and 
coca as well as the volume of illicit drugs being produced for export to the United States; increasing 
the amount of illicit drugs seized before entering the United States; increasing the amount of forfeited 
assets; increasing the number of convictions for drug-related crimes; and increasing the pace of review 
of, and imposition of international controls on, emerging dangerous substances.
Achieving the President’s outcome of reducing the number of Americans losing their lives to drug 
addiction in today’s crisis, and preparing now to dominate the drug environment of the future, requires 
deliberate actions focused on clear priorities and tangible outcomes to reduce the availability of 
drugs in our Nation. However, lasting success requires those actions to complement, and be informed 
by, a strong domestic public health response to reduce the use of these drugs in the United States 
which makes possible enormous profits for drug traffickers and fuels the illicit drug market. Bold and 
decisive national security, law enforcement, and public health efforts are needed to lift the Nation 
from the shadow of drug use and move toward the President’s goal of a stronger, healthier, and drug-
free society today and in the years to come.
GOALS AND BUDGET PROJECTIONS
While this Strategy focuses on aggregate progress toward a strategic outcome rather than enumerating 
all of the tasks and activities that organizations at the Federal, State, local and Tribal levels must 
undertake in order to stem the tide of America’s drug crisis, it is nonetheless important to establish 
objectives that align to the Strategy’s nine goals for achieving the overarching strategic outcome of 
saving American lives and building a healthier, drug-free society. This not only ensures the necessary 
policies, priorities, and objectives of drug control agencies and interagency partners are adequately 
aligned and resourced to advance the President’s drug control priorities, but also serves to identify 
those areas where a refinement of the Strategy may be necessary to close an identified gap, or areas 
where a shift in specific agency focus or resources can attain greater effects in achieving the President’s 
overarching strategic objective.
Goals for Reducing Illicit Drug Use, Objectives, and Targets for 
Measuring Progress
This Strategy’s three lines of effort: preventing drug use before it starts, providing treatment leading 
to long-term recovery for those suffering from substance use disorder, and reducing the availability 
of drugs in the United States, will be advanced by the accomplishment of the nine goals listed below. 
Each goal directly supports the three lines of effort and contains one or more quantifiable and 
measurable objectives. The Strategy, with its three lines of effort, describes in detail how the aggregate 
progress across the interagency directly contributes to the achievement of the nine goals. Assessing 
the sustained progress toward achieving those objectives, and realizing the related goals, is enabled 
by annual targets that will be continually assessed over a five year period.3  
3The accompanying Performance and Reporting System contains each of the annual targets for each Objective 
and a detailed description of how each was determined.
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A description of how each goal and its supporting objective(s) was determined, including the data, 
research, or other information used to inform the determination to establish them, is discussed in the 
National Drug Control Strategy: Performance Reporting System. The baseline for all objectives is 2017, the 
first year of the Administration, except for three objectives for which the earliest data is for either 2018 
or 2019. Development of the goals and objectives was an iterative process conducted by review of the 
latest research and data and consultation with subject matter experts within ONDCP and from the 
relevant National Drug Control Program Agencies.
•	 Goal 1: The number of Americans dying from a drug overdose is significantly reduced within 
five years. 
o Objective 1: Overdose deaths are reduced by reaching annual targets in percentage 
reductions each year, and by a total of 15 percent by 2022.
•	 Goal 2: Educate the public, especially adolescents, about drug use, specifically opioids. 
o Objective 1: Reduce the rate of past year use of any illicit drug among youth each year, 
and by 15 percent by 2022. 
o Objective 2: Reduce the rate of past year use of opioids among youth each year, and by 
15 percent by 2022.
•	 Goal 3: Evidence-based addiction treatment, including MAT for opioid addiction, is more 
accessible nationwide. 
o Objective 1: Increase the percentage of specialty treatment facilities providing 
Medication-Assisted Treatment for opioid use disorder every year, so that 100 percent 
do so by 2022. 
o Objective 2: Increase the percentage of Federal health care workers certified to 
administer, prescribe, and dispense buprenorphine for opioid use disorder every year, 
and to 10 percent by 2022.
•	 Goal 4: Increase mandatory prescriber education and continuing training on best practices 
and current clinical guidelines. 
o Objective 1: Increase the percentage of Federal prescribers that have completed 
continuing education on best practices and current clinical guidelines in prescribing 
opioid medications every year, and by 50 percent by 2022.
•	 Goal 5: Reduce nationwide opioid prescription fills. 
o Objective 1: By increasing education and adherence to proper prescribing practices 
for effective pain management, reduce nationwide opioid prescription fills every year, 
and by 33 percent by 2020 and maintain that reduction in 2021 and 2022.
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•	 Goal 6: Increase Prescription Drug Monitoring Program interoperability and usage across the 
country. 
o Objective 1: Increase the number of states integrating electronic health records with 
their Prescription Drug Monitoring Programs every year, and to 30 by 2022. 
•	 Goal 7: Significantly reduce the availability of illicit drugs in the United States by preventing 
their production outside the United States. 
o Objective 1: Reduce potential production of cocaine (pure metric tons) in Colombia 
every year, and by 42 percent by 2022. 
o Objective 2: Reduce potential production of heroin (pure metric tons) in Mexico every 
year, and by 25 percent by 2022. 
•	 Goal 8: Significantly reduce the availability of illicit drugs in the United States by disrupting 
their sale on the internet, and stopping their flow into the country through the mail and express 
courier environments, and across our borders. 
o Objective 1: Increase the amount of cocaine removals (in metric tons) in the transit 
zone every year, and by 10 percent by 2022. 
o Objective 2: Increase the amount of seizures (in metric tons or kilograms) at the U.S. 
southern border every year, and by 10 percent by 2022 for each of the following drugs: 
cocaine, fentanyl, heroin, and methamphetamines. 
o Objective 3: Increase the number of online drug vendor investigations every year, and 
by 20 percent by 2022.
•	 Goal 9: Illicit drugs are less available in the United States as reflected in increased price and 
decreased purity as measured by price per pure gram. 
o Objective 1: Increase the average price per pure gram of cocaine every year, and reach 
$250 by 2022. 
o Objective 2: Increase the average price per pure gram of heroin every year, and reach 
$1,400 by 2022. 
o Objective 3: Increase the average price per pure gram of methamphetamine to $120 
by 2022. 
o Objective 4: Increase the cost of illicit fentanyl (purity not known) charged by dealers 
per kilogram to customers every year, and by 10 percent to $3,300 by 2022.
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Projections for National Drug Control Program and Budget 
Priorities
The 2019 Strategy set policy goals and objectives for the Nation, along with associated performance 
measures and targets to achieve those goals and objectives. ONDCP considers the Strategy’s 
projections for policy priorities to be the budget priorities because they indicate to the National Drug 
Control Program Agencies what the Administration’s long-term priorities are, and those agencies are 
expected to provide resources for those priorities over the course of the Administration. ONDCP’s 
funding guidance also establishes the budget priorities—for the current and future years—for National 
Drug Control Program agencies to meet the performance targets and achieve the policy goals and 
objectives of the Strategy.
Budget and Performance Summary
The FY2020 Budget and Performance Summary, published in May 2019, can be found at: 
https://www.whitehouse.gov/wp-content/uploads/2019/05/FY-2020-Budget-and-Performance.pdf
ONDCP will release the National Drug Control Strategy: FY 2021 Budget and Performance Summary 
(Budget Summary) after the President’s proposed budget is released in early 2020. The Budget Summary 
contains information on the President’s FY 2021 drug control budget, as well as the enacted and 
actual funding levels for FY 2020 and FY 2019, by National Drug Control Program Agency (NDCPA) and 
subordinate elements, as well as historical funding levels by function. Appendices contain information 
on the resources to support the National Drug Control Strategy Border Strategies and the National 
Treatment Plan. In addition, the Budget Summary provides a description of each agency’s mission, 
program descriptions, and significant changes in the FY 2021 request compared to the FY 2020 enacted 
or continuing resolution amount. The FY 2021 Budget Summary also contains details of each agency’s 
program performance metrics and a section on the assessment of the contribution of each NDCPA to 
achieving the goals and objectives of the Strategy. 
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Appendix 1: List of Supporting Planning Documents
The National Drug Control Strategy has six supporting plans or documents that address specific 
requirements necessary for achieving the Strategy’s overarching strategic outcome and the nine goals, 
objectives, and targets used to assess performance. Taken together, the base Strategy and its six 
supporting plans and documents compose the Administration’s National Drug Control Strategy:
•	 National Drug Control Strategy: National Treatment Plan—articulates how the Federal Departments 
and Agencies and their key stakeholders at the State, local, Tribal, and private sectors of society will 
expand treatment for substance use disorders.
•	 National Drug Control Strategy: Southwest Border Counternarcotic Strategy—articulates the 
Government’s strategy for preventing the illegal trafficking of drugs across the international border 
between the United States and Mexico, including through ports of entry and between ports of entry 
on the border.
•	 National Drug Control Strategy: Northern Border Counternarcotic Strategy—articulates the 
Government’s strategy for preventing the illegal trafficking of drugs across the international border 
between the United States and Canada, including through ports of entry and between ports of 
entry on the border.
•	 National Drug Control Strategy: Budget and Performance Summary Report—presents the details of 
the President’s resource requirements to implement the Strategy and to inform Congress and the 
public about the total amount proposed to be spent on all supply reduction, demand reduction, 
State, local, and tribal affairs, including any drug law enforcement, and other drug control activities 
by the Federal Government. There are 16 Federal Departments and Agencies that have been 
designated by the ONDCP Director as Drug Control Program Agencies. Budget detail is provided 
at the program, project, and activity levels (the level at which the Office of Management and 
Budget and the agencies request funding and Congress appropriates it). The report also provides 
detail on agency-level performance metrics to enable assessment of progress toward achieving 
programmatic objectives.
•	 National Drug Control Strategy: Performance Reporting System—describes the Strategy’s goals, 
objectives, and annual targets established for reducing drug use, availability, and the consequences 
of drug use.
•	 National Drug Control Strategy: Data Supplement—provides the data that enables an assessment 
of current drug use and availability, impact of illicit drug use, and treatment availability. The more 
than 150 data tables provide national, state, local, and international data on drug use; attitudes and 
perceptions toward drug use; drug- induced morbidity and mortality; drug treatment; drug-related 
crime, including drugged driving; drug price and purity; cultivation and/or the production of drugs; 
and drug eradication and seizures.
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Appendix 2: ONDCP’s Role in Facilitating the Achievement of the 
Strategic Goals and the Coordination Mechanisms Necessary for 
Achieving the Strategic Goals
ONDCP’s Role: Established by the Anti-Drug Abuse Act of 1988, and reauthorized by the SUPPORT 
for Patients and Communities Act (Public Law 115-271), ONDCP leads, coordinates, and oversees the 
implementation of the national drug control policy, including this Strategy. There are numerous 
facilitation mechanisms that the Director of the National Drug Control Policy uses to achieve the nine 
goals and objectives of this Strategy, the most important of which are the two National Coordination 
Groups within ONDCP and the specific functional coordinators discussed below. In addition, the 
Director, in conjunction with ONDCP’s Office of Performance and Budget, conducts a yearly evaluation 
of the effectiveness of this Strategy in light of the activities and accomplishments of the National Drug 
Control Program Agencies. 
Existing Coordination Mechanisms:
National Cocaine Coordination Group (NCCG): Responsible for guiding and synchronizing interagency 
efforts to reduce the availability of cocaine. The NCCG identifies gaps and redundancies in Federal 
government’s efforts to address the cocaine problem set and works to solve them in order to achieve 
its goal of reducing the number of fatal overdoses. The NCCG works with the National Security Council 
(NSC), Domestic Policy Council (DPC), and other White House elements, as appropriate, on issues 
involving counternarcotics, Colombia, Peru, transnational organized crime, and the implementation of 
the 2019 National Drug Control Strategy.
National Opioids and Synthetics Coordination Group (NOSCG): The focal point for guiding and 
synchronizing interagency efforts to reduce the availability of all illicit or illegally trafficked opioids, 
plant-based and synthetic, as well as psychostimulants such as methamphetamine. To achieve its 
primary measure of effectiveness, reducing the number of fatal overdoses, the NOSCG identifies gaps 
and redundancies in the Federal government’s efforts to address the opioid and synthetics problem set 
and works to close them. 
To do so, the NOSCG coordinates widely across the interagency and with partners in the private sector 
and the state-level and below, starting with ten engagements per month in direct support of the 
implementation of its Heroin Availability Reduction Plan. These engagements include a weekly TS-SCI 
video teleconference (VTC) with all Intelligence Community partners; a monthly VTC with US Embassy 
Mexico to align and coordinate counternarcotics and security activities and issues; a monthly VTC with 
US Embassy Beijing to coordinate and align policy issues related to synthetic opioids; a monthly Federal 
law enforcement Secure VTC to share information on emerging trends; a monthly nationwide webinar 
with 20 partner states in all four US census regions that brings together law enforcement and public 
health officials to share trends, best practices, and lessons learned; and a monthly teleconference to 
allow forensic scientists, medical examiners, coroners, intelligence analysts, and members of the law 
enforcement community to share trend data and information on newly identified substances seized by 
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U.S. Customs and Border Protection (CBP).
The NOSCG also co-chairs or supports NSC-led sub-policy coordinating committees, policy coordinating 
committees, and deputies committee meetings as appropriate on issues involving counternarcotics, 
Mexico, China, illicit finance, transnational organized crime, and special interest topics such as the 
Community Response to Drug Overdose and the safe handling of illicit fentanyl for first responders. Along 
with the DPC, the NOSCG co-chairs meetings on public health-related topics such as prescription drug 
monitoring programs, safe prescribing, naloxone availability and use, and increasing the availability of 
MAT for opioid use disorder. The NOSCG also organizes, leads, or participates in White House stakeholder 
events on specific topics for private sector partners such as private sector cooperation on stemming 
the flow of synthetic opioids and counterfeit prescription drugs into the United States, and overdose 
response and Naloxone availability in colleges and universities. Finally, the NOSCG supports both the 
NSC and DPC to co-chair meetings on implementation of the 2019 Strategy, providing subject matter 
and policy expertise on those strategy objectives related to opioids, illicit opioids, synthetic drugs, dark 
web drug sales, and illicit finance. 
Demand Reduction Coordinator and Public Health, Education and Treatment Task Force (PHET): 
The Demand Reduction Coordinator leads ONDCP’s Public Health, Education, and Treatment Task Force 
which establishes the ONDCP response to the Nation’s addiction crisis, and provides strategic guidance 
to lead the interagency effort to plan, coordinate, and manage the public health responsibilities of the 
President’s Strategy. The task force portfolio includes primary drug prevention, public education on 
the consequences of drug use, removing barriers to access effective addiction treatment including 
medication assisted therapies, criminal justice diversion programs, and establishing recovery support 
programs. Collaboration and coordination with other Federal agencies, State, local and Tribal health 
officials, and health policy-related interest groups is key to the development and implementation of 
these demand reduction functions.
United States Interdiction Coordinator (USIC): Responsible for establishing the Federal government’s 
interdiction strategy and assessing the sufficiency of assets committed to illicit drug interdiction. To 
accomplish this, the USIC staff works across four primary lines of effort: border strategy development, 
information sharing, interdiction capability and capacity development and support, and interagency 
coordination. The USIC publishes the Administration’s National Interdiction Command Control Plan 
(NICCP) and multiple border strategies in support of the of the President’s Strategy. To develop and 
implement these availability reduction functions, the USIC collaborates with White House peers, 
international partners, Federal, State, local, and Tribal law enforcement officials, and the HIDTAs.
State, Local, and Tribal Affairs Coordinator (SLTAC): Coordinates drug control efforts between 
Federal agencies and State, local, and Tribal governments. The SLTAC meets with State, local, and Tribal 
governments to hear their concerns and coordinate their drug control efforts with the drug control 
efforts of the Federal agencies. This helps to ensure cooperation and information sharing, and to avoid 
duplication between Federal efforts and State, local, and Tribal efforts. The SLTAC also ensures that 
State, local, and Tribal governments commit to and take steps to achieve the Strategy’s goals. 
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Emerging Drug Threats Coordinator: Chairs the Emerging Threats Committee that is responsible for 
recommending to the Director the criteria for declaring or terminating an emerging or evolving drug 
threat in the United States, monitoring, discussing, and identifying an evolving and emerging drug 
threat in the United States, and recommending to the Director when such a declaration or termination 
needs to be made. In the case of a declaration, the Chairperson and the Committee are responsible for 
developing, coordinating, and overseeing the execution of a Response Plan to address the drug threat 
as outlined in 21 USC §1708: Emerging Threats Committee, plan, and media campaign.
Performance Budget Coordinator: Responsible for ensuring the Director has sufficient information 
necessary to analyze the performance of each National Drug Control program Agency, the impact Federal 
funding has had on the goals in the Strategy, and the likely contributions to the goals of the Strategy 
based on funding levels of each National Drug Control Program Agency, to make an independent 
assessment of the budget request of each agency; and advising the Director on agency budgets, 
performance measures and targets, and additional data and research needed to make informed policy 
decisions.
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Appendix 3: Mission Statement and List of National Drug Control 
Program Agencies and How They Help Achieve the Strategic Goals 
The National Drug Control Program’s mission is to develop policies and to coordinate, promote, and 
implement initiatives that result in a stronger, healthier, drug-free society today and in the years to 
come. This mission is implemented through a series of congressionally mandated activities set forth 
in the agency’s authorizing legislation, as well as through strategic initiatives aimed at preventing the 
initiation of illicit drug use, providing treatment services leading to long-term recovery for those suffering 
from addiction, and aggressively reducing the availability of illicit drugs in American communities.
The National Drug Control Program Agencies are the Departments of Agriculture, Defense, Education, 
Health and Human Services, Homeland Security, Housing and Urban Development, Interior, Justice, 
Labor, State, Transportation, Treasury, and Veterans Affairs, the Federal Judiciary, the Office of National 
Drug Control Policy, the United States Postal Inspection Service, and the Court Services and Offender 
Supervision Agency for the District of Columbia.
ONDCP has a performance evaluation plan for the nine goals of the Strategy that includes performance 
measures for each National Drug Control Program Agency, to the extent practicable, sets performance 
targets for those measures, and presents an estimate of the Federal funding needed to achieve 
performance targets and objectives. The Strategy establishes the long-range goals for reducing illicit 
drug use and the consequences of illicit drug use. The performance measures and targets that support 
the policy objectives of the Strategy are described in the National Drug Control Strategy: Performance 
Reporting System (PRS). ONDCP collaborates with National Drug Control Program Agencies to align their 
activities that support implementing the Strategy’s policy objectives to the PRS performance targets. 
ONDCP also collaborates with agencies to establish agency-specific performance measures and targets 
to assist ONDCP and the agencies in evaluating their contributions to achieving Strategy goals. This 
agency-specific performance data is presented in the Performance section of the National Drug Control 
Strategy: Budget and Performance Summary (Budget Summary). The budget request for the agency, also 
presented in the Budget Summary, describes the resources needed to meet the agency’s performance 
targets, and ensures their contribution to achieving the performance goals and objectives of the 
Strategy. ONDCP’s construct for performance evaluation planning allows it to assess the government’s 
effectiveness in achieving policy objectives by aligning agency funding and performance to the strategic 
goals and policy priorities of the Strategy.
For a more in-depth description of the role of each NDCPA, their related programs, assets and activities 
to achieve Strategy goals, please refer to the FY 2020 Budget and Performance Summary that was 
published in May 2019, and to the FY 2021 Budget and Performance Summary that will be published 
after the President’s proposed Budget is released.
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Appendix 4: Role of Key Stakeholders and Partners in the Strategy
ONDCP, established by the Anti-Drug Abuse Act of 1988, and reauthorized by the SUPPORT for 
Patients and Communities Act (Public Law 115-271), is required to consult a wide array of experts, key 
stakeholders, and officials while developing the President’s National Drug Control Strategy. It requires 
the ONDCP Director to work with the heads of the National Drug Control Program agencies; ONDCP’s 
internal coordinators; the Interdiction Committee and the Emerging Threats Committee; appropriate 
Congressional Committees; State, local and Tribal officials; private citizens and organizations with 
experience and expertise in demand and supply reduction; and appropriate representatives of foreign 
governments. ONDCP met this requirement by soliciting the views of the following individuals and 
organizations during the development of the National Drug Control Strategy as detailed below.
Consultation with National Drug-Control Program Agencies (21 USC § 1705(b)(4)(A)(i))
ONDCP works closely with agencies that have been charged to oversee drug prevention, treatment and 
recovery, and availability reduction. Input was solicited from fifteen Federal Departments, Independent 
Agencies, and the Federal Judiciary. ONDCP works regularly throughout the interagency (including the 
NSC and the DPC) to ensure the effective coordination of drug programs. These agencies, based on their 
unique mission, roles, functions, will play key roles in achieving all nine goals contained in the strategy 
Consultation with ONDCP coordinators (21 USC § 1705(b)(4)(A)(ii))
The various coordinators within ONDCP (the Performance Budget Coordinator, the Interdiction 
Coordinator, the Emerging and Continuing Threats Coordinator, the State, Local, and Tribal Affairs 
Coordinator, and the Demand Reduction Coordinator) are each an integral part of the development of 
the Administration’s policy and budget priorities in the areas of prevention, treatment and recovery, 
and reducing the availability of illicit drugs. Each coordinator contributed to the development of the 
Strategy and will play key roles in achieving the nine goals.
Consultation with Interdiction and Emerging Threats committees (21 USC § 1705(b)(4)(A)(iii))
ONDCP serves a leadership role on both the Interdiction Committee (TIC) and the Emerging Threats 
Committee, and engaged both groups to gather their views on the Strategy. The TIC works to enhance 
and expand cooperation and coordination with all agencies engaged across the operational spectrum 
of supply reduction and interdiction. Similarly, the new Emerging Threats Committee has established 
the criteria for declaring or terminating an evolving or emerging drug threat, and it is monitoring the 
landscape to identify such threats in the United States. Both Committees’ perspectives were essential 
when considering both the public health and public safety aspects of the Strategy. The Interdiction 
Committee will have a significant role in achieving Goals 1, 7, 8, and 9 of the Strategy. The Emerging 
Threats Committee has members from the Prevention, Treatment and Recovery, and the Interdiction 
(law enforcement) communities, they will play key roles across the three lines of effort and with each of 
the nine goals. 
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Consultation with appropriate Congressional committees (21 USC § 1705(b)(4)(A)(iv))
The Administration works closely with the Congress in the development, implementation, oversight, 
and funding of the National Drug Control Strategy. ONDCP requested input from over 250 members of 
the House and Senate who sit on the House Oversight and Reform, Judiciary, Energy and Commerce, 
and Appropriations Committees, as well as the Senate Drug Caucus, Judiciary, Health, Education, Labor 
and Pensions and Appropriations Committees. Their input, as well as the continued interaction between 
Administration and Congress, was critical to the development of this Strategy.
Consultation with State, local, and Tribal officials (21 USC § 1705(b)(4)(A)(v))
ONDCP meets, interacts and consults regularly with State, local and Tribal officials when implementing 
the Strategy. Governors from all states and territories, regional commissions, Tribal leaders, local 
prevention experts, and public health and public safety officials (including those at the HIDTAs) were 
asked to provide input in the areas of prevention, treatment, and availability reduction. These views are 
important because they offer insight into local drug policy issues as well as potential solutions. These 
communities draw from key stakeholders in the Prevention, Treatment and Recovery, and Reducing the 
Availability of Illicit Drugs arenas, so they will have an important role in achieving all nine goals.  
Consultation with private citizens and organizations (21 USC § 1705(b)(4)(A)(vi and vii))
ONDCP solicited input from a comprehensive array of nonprofit organizations, governmental 
associations, medical associations, health plans and issuers, drug policy stakeholders, community 
anti-drug coalitions, professional associations, research and educational institutions, and faith-based 
organizations representing the interest of both the supply-side and demand reduction communities. 
These citizens and organizations span all three lines of effort and will, therefore, have significant 
responsibility for achieving all nine objectives.
Consultation with foreign governments (21 USC § 1705(b)(4)(A)(viii))
ONDCP and the interagency works regularly with the international community to confront transnational 
criminal organizations, reduce illicit production, and protect citizens and democratic institutions from 
corruption or subversion. ONDCP requested input from both a number of partner nations as well as 
global and regional organizations including the United Nations Office on Drugs and Crime and the 
International Narcotics Control Board. Foreign governments are involved in preventing initiates to drug 
use, providing treatment services to move people into long-term recovery, and for interdicting the flow 
of drug into their countries and around the globe. This strategy will rely on the expertise and capabilities 
of our foreign partners across the three lines of effort and the related nine goals.
Review of Stakeholders’ Drug Control Activities and Their Role in Achieving the Strategic Goals (21 USC § 
1705(c)(1)(E) and (F)(ii))
ONDCP routinely examines how international, state, local, tribal, and the private sectors’ activities align 
with the strategy to facilitate a coordinated and effective drug control system at all levels of government. 
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We do that through the strategy consultation process, in the annual performance review of the strategy, 
and in ongoing community outreach. The Strategy is not intended to enumerate every activity the 
Federal government and key stakeholder must execute in order to achieve our common vision, but it 
articulates a common way forward for stakeholders in academic, civic, government, law enforcement, 
and public health communities at the Federal, state, local, and tribal level to take collective action to 
address the crisis challenging communities across America. It is only through a united and unified effort 
in which the Federal government works with, and in support of, creative and resourceful individuals and 
organizations across the country and with our international partners, that we can address this complex 
national security, law enforcement, and public health problem.
Regarding stakeholders’ consultation, as noted in the introduction of the Strategy, ONDCP relied heavily 
on the expertise of the stakeholders discussed above during the consultation and development phases 
of the Strategy. Their input was decisive in determining the nine goals as well as the underlying activities 
we must accomplish in order to achieve the strategic outcome of building a stronger, healthier, drug-free 
society and reducing the number of Americans losing their lives to drug addiction. More information 
regarding how stakeholder input helped to inform the strategy’s goals can be found in the Performance 
Reporting System.  
Stakeholders and their activities are also important in implementing the goals of the Strategy. The 
following bullets outlines major groups of stakeholders and include a sampling of their current activities 
and their role in facilitating the achievement of the Strategy’s goals:
•	 Prevention Organizations: Prevention organizations engage in a variety of activities and programs 
to prevent people, especially young people, from initiating drug use.  Some focus on education 
in schools, while others are more broadly community-based. These prevention organizations 
will play an important role in implementing the prevention line of effort and Strategy Goals 
1, 2, and 5. For example, the stakeholders can help achieve the strategic goals through early 
recognition and addressing risky substance use which can help interrupt the trajectory towards 
more chronic substance use disorders. They would also do so through increasing the quantity 
and quality of prevention education, and in particular by making such prevention programs 
evidence-based.  
•	 Public Health, Treatment, and Recovery Organizations: Public health, treatment and recovery 
organizations provide drug treatment to those with addictions, ensure sustainable recovery for 
those in recovery from addictions, and address broader public health concerns such as conditions 
associated with drug use. These public health, treatment, and recovery organizations will play 
an important role in implementing the treatment and recovery line of effort and Strategy Goals 
1, 3, 4, and 5. For example, they would do so through increasing the quantity and quality of 
addiction treatment and recovery programs, and in particular by making such treatment and 
recovery programs evidence-based. Once an individual is in recovery, stakeholders can help 
achieve the strategic goals by creating mutually-supportive communities where the individual 
can improve their physical, mental, spiritual, and social well-being and gains skills and resources 
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to sustain their recovery.
•	 Law Enforcement Organizations: Law enforcement organizations stop drug trafficking through 
targeting drug trafficking organizations and reducing availability of drugs, and can assist 
with public health efforts through the criminal justice system as well. These law enforcement 
organizations will play an important role in implementing the Availability Reduction line of effort 
and Strategy Goals 1, 8, and 9. For example, these are numerous activities conducted by National 
Drug Control Program Agencies that enhance and coordinate domestic law enforcement efforts 
leading to reduced drug-related violence and property crime as well as substance use and 
availability. Law enforcement action would result in the further disruption of the evolving illicit 
drug supply chain and increase the amount of drugs seized before entering the United States.
•	 State, Local and Tribal Governments: State, local, and tribal governments play roles on both the 
public health and law enforcement aspects of the Strategy, and they are key partners of ONDCP 
and Federal agencies in all aspects of drug control. They often organize and fund various public 
health, prevention, and treatment efforts for drugs. They also run state, local, and tribal law 
enforcement agencies, which is where the majority of national drug prosecutions occur. State, 
local and tribal governments will play an important role in implementing all of the Strategy’s 
lines of effort and goals. It is only through a unified effort in which the Federal government 
works with, and in support of, the creative and resourceful individuals at the State, Local, and 
Tribal level of government that we can successfully address this complex national security, law 
enforcement, and public health problem. 
•	 International Organizations and Foreign Governments: International organizations and foreign 
governments play a role in working with U.S. agencies and law enforcement in particular to 
reduce source country production of drugs and interdict traffickers. International organizations 
and foreign governments will play an important role in implementing primarily the Availability 
Reduction line of effort and Strategy Goals 1, 7, and 9. For example, National Drug Control Program 
agencies conduct activities to reduce illicit drug availability by assisting our international 
partners in managing the consequences of drug production; trafficking; consumption in their 
own societies, including training and equipping security forces; raising awareness of science-
based practices and programs to prevent, treat and recover from substance use disorder; and 
supporting economic development programs primarily intended to reduce the production 
and trafficking of illicit drugs. By taking advantage of the strong multilateral framework that 
exists to address the global drug problem, particularly in terms of supporting the three drug 
control conventions and providing leadership in the processes for internationally scheduling, 
controlling, and monitoring illicit drugs and their precursor chemicals, we will continue to 
advance the strategic goals.
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Appendix 5: National Drug Control Strategy Research and Data Collection 
Plan
Scope & Criteria for Policy Questions: While there are a range of data collection and research activities 
germane to the implementation of the National Drug Control Strategy, this data research plan focuses 
its policy questions on the identification and analysis of emerging or increasing trends that may require 
significant shifts in strategy, approach, or resource allocation to identify if we are postured to deal with 
these drug trends. This initial plan does not provide programmatic details outlining our progress.
As per the requirements of 21 U.S.C. § 1705(c)(1)(M), this plan also: 
•	 Identifies data required to answer each question; 
•	 Explains how data will be collected, analyzed and applied; 
•	 Describes data collection and analysis challenges, such as data availability, data timeliness 
and integrity, and data sharing constraints; and, 
•	 Details the steps ONDCP and drug control agencies will take to implement the plan. 
Research Plan Policy Question (RPPQ) 1:
•	 Question:  What new or emerging drugs or significant shifts in U.S. illicit drug use patterns may 
require changes in law enforcement or public health strategies, resource allocation or national 
strategy or priorities? 
o Do these trends include significant shifts in primary drug of choice, prevalence, route of 
administration, forms of poly drug use, overdose, use-related co-morbidities and mortality, 
or other consequences?
o Are there trends that require an emergency or alternative response at the national, regional, 
state, or local levels? 
This information would give senior policymakers the latest illicit drug use patterns, including 
emerging drugs to enable early detection and a rapid public health and public safety response to, 
ultimately, reduce morbidity and mortality.
•	 Data or Datasets:  Current data systems such as the National Survey on Drug Use and Health 
(NSDUH), the Healthcare Cost and Utilization Project (HCUP), and the National Emergency Medical 
Services Information System (NEMSIS) provide information on the latest illicit drug use trends for 
the most commonly used substances. 
NSDUH surveys a statistical sample of Americans living in households about their alcohol and 
other drug use and their mental health status, but does not collect adequate information on the 
use of emerging drugs. Administrative hospital billing records from HCUP can provide data on 
inpatient stays and emergency department visits related to non-fatal drug overdoses, based on 
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physician diagnoses and International Classification of Diseases, 10 Revision, Clinical Modification 
(ICD-10-CM) codes, but may not be corroborated with toxicology testing. NEMSIS provides data 
from Emergency Medical Service patient records resulting from an emergency 911 call, including 
non-fatal drug overdoses, however a toxicological test result is usually not included in the record. 
Postmortem testing can currently measure new or changing patterns of drug use. 
•	 Methods or Analytical Approach: The U.S. Government can monitor emerging drugs by testing 
individuals at high risk—such as probationers, emergency-room patients, and the drug treatment 
population—for their drug use to get a better warning of new drugs of abuse. To achieve this 
testing, the US Government should establish a sentinel warning system—a system that actively 
monitors high-risk drug using populations—that conducts urinalysis tests on a broad panel of 
substances beyond those most commonly encountered. For example, the Community Drug Early 
Warning System (CDEWS) study was a pilot for such a sentinel system. CDEWS retested previously 
collected urine samples from populations very likely to use drugs. Results revealed that these high-
risk populations commonly used multiple drugs that would not be detected using a traditional 
toxicology panel. Finally, systematic monitoring of online drug fora like Bluelight, Reddit, and 
Erowid via an artificial intelligence data mining interface may shed light on the substances current 
drug users are seeking out and purchasing.
•	 Challenges or Deficiencies: Existing data systems, such as NSDUH, HCUP, or NEMSIS are 
constrained by their design to report on drugs that are already commonly used and provide little 
or no insight into emerging drugs or use patterns. While postmortem testing can currently measure 
new or changing patterns of drug use, variations in local toxicological forensic testing and delays 
in national standardization and reporting limit its use as an early detection capability. Enhanced 
frontline surveillance systems could be further developed to identify emerging national and local 
drugs and trends, subject to the availability of funding.
RPPQ 2:
•	 Question:  Are significant shifts occurring in the domestic illicit production of synthetic drugs and 
other emerging substances?
This information will provide senior policymakers an understanding of the latest domestic drug 
production threat.
•	 Data or Datasets:  The National Seizure System (NSS) collects domestic data on illicit drug and 
laboratory seizures. 
•	 Methods or Analytical Approach: The DEA’s Signature Programs, which determines the likely 
source country of a small sample of heroin and cocaine seizures, could potentially help identify 
domestic production. CBP palynologists have successfully used pollen testing to identify the 
geographic origin of seized fentanyl and related substances. Analysis of pollen and other residual 
organic matter have enabled palynologists to identify provinces in China where fentanyl has been 
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packaged, and shows promise for better identifying the source country of synthetic drugs. This 
method could be further tested to determine if it could be applied to domestic pollen to determine if 
a drug was produced in the United States. The U.S. Government also monitors domestic laboratory 
seizures of illicit synthetic drugs as an indicator of domestic production. For example, estimated 
levels of domestic methamphetamine production are assumed to be low because numbers of 
domestic laboratory seizures are few. Forensic analysis—the collection, analysis, and reporting of 
information critical to investigations by law enforcement—can also provide insight into domestic 
production trends.
•	 Challenges or Deficiencies: While the U.S. Government has some domestic production statistics, 
real-time surveillance of domestic production is limited. Also, due to the United States’ negligible 
drug production, it is not among the countries for whom a source signature has been established. 
Source country signature analysis is not possible for synthetic drugs in the same fashion as plant-
based drugs, like heroin and cocaine. DEA’s labs and signature programs could test a greater 
proportion of seized drug material for content, purity, and source country signature.  CBP’s 
palynology department could be expanded to geo-locate the packaging source location of a 
greater proportion of seized synthetic drugs. In tandem, consistent law enforcement resources 
need to be applied toward regular monitoring for and detection of domestic clandestine drug labs. 
RPPQ 3:
•	 Question: Are criminal actors exploiting new vectors (e.g., transshipment locations, methods of 
smuggling) for U.S. bound illicit substances? 
Senior policymakers need this information to ensure activities are prioritized toward the greatest 
concealment threats.
•	 Data or Datasets: Existing law enforcement seizure databases can provide some insight into current 
vectors of illicit substances. However, information about drug trafficking trends and common 
concealment methods are typically derived from targeted and time-limited intelligence gathering 
and law enforcement operations. For example, the El Paso Intelligence Center (EPIC) provides 
tactical intelligence to Federal, state, and local law enforcement agencies on a national scale—at 
times identifying new concealment methods in its intelligence reports.  
•	 Methods or Analytical Approach: Policymaker understanding of the drug trafficking and use 
environment is essentially based upon three things; an in-depth understanding of the environment 
as it is, valid and necessary assumptions about how it will change over time, and a collective 
understanding about how actions can be taken to shape that environment in order to achieve the 
strategy’s long-term goal, in this case to reduce the number of Americans dying from drug use. 
To do this policymakers rely upon a large body of reporting and datasets that each have unique 
capabilities and limitations. Law enforcement seizure data provides insight into the types of drugs 
seized during law enforcement operations within the United States, their value, and their purity. 
Seizure data from ports of entry identify the volume and variety of drugs seized as traffickers attempt 
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to bring them into the United States. Chemical signature and profiling data tells us the geographic 
origin of plant-based drugs or the chemical composition of synthetic drugs, and crop estimate data 
provides the magnitude of plant-based drug production in other countries that produce drugs for 
the US market. Similarly, public health data provides us insight in the size, behaviors, preferences, 
and usage patterns among the drug using population, as well as longitudinal trends in drug us 
across the country over time. Moreover, public health information is used to identify many of the 
consequences of drug use for individuals, families, and communities.  Although each of these 
individual data sources have known limitations, taken together they can provide the most complete 
available understanding of drug availability and use in the United States. More importantly, they 
allow policymakers to identify changes in that environment to identify whether or not the strategy’s 
assumptions remain valid, and to see if there are gaps in our Federal government capability that 
need to be filled through regulatory, legislative, or resource changes. 
•	 Challenges or Deficiencies: Whether law enforcement agencies activities are normative, 
generalizable, or scalable is difficult to judge absent consolidated law enforcement databases 
establishing baseline trends. Policymakers also have difficulty judging what front-end resources 
(e.g., detection technologies, person-power, screening levels) are most impactful against these 
new event types. Considerable ongoing interagency collaboration would be required to establish 
incoming and outgoing vector baseline thresholds, the operational and process requirements and 
maintenance of a consolidated data system, and the most effective use of detection technologies. 
Significant and efforts in technology, law enforcement operational capacity, big database 
architecture, and randomized data collection and analysis would be required to improve detection 
capabilities for new and under-resourced vectors, develop a consolidated data system that is 
useful both operationally and for policymakers, and establish baselines for specific locations and 
concealment methods. 
RPPQ 4:
•	 Question: How well does substance use disorder treatment capacity (e.g., opioid treatment 
programs, residential treatment facilities, office-based opioid treatment, and outpatient specialty 
treatment) respond to new or emerging shifts in drug use within the United States?
o Is a shift in resource allocation required to better respond to needs?
Senior policymakers need this information to determine if there is sufficient treatment support 
and to ensure that resources are appropriately targeted as domestic drug use shifts.
•	 Data or Datasets: Current surveys such as the NSDUH and the Monitoring the Future (MTF) provide 
information on the latest illicit drug use trends for the most commonly used substances for 
adults and youth. The Treatment Episode Data Set (TEDS) provides demographic and substance 
use characteristics of admissions to treatment for abuse of alcohol or drugs, while the National 
Survey of Substance Abuse Treatment Services (N-SSATS) collects data on the location, scope, and 
characteristics of substance abuse treatment facilities throughout the United States.
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•	 Methods or Analytical Approach: Compare use and treatment admission data at the state, 
regional, and local levels to available treatment capacity to identify potential discrepancies 
between treatment availability and need. 
•	 Challenges or Deficiencies: There is no data source that provides real-time available treatment 
capacity that can be cross-referenced against drug trends in demand.
Director’s Next Steps:
The Director will establish an Interagency Drug Research Group composed of individuals from the 
National Drug Control Program Agencies chaired by ONDCP to effectuate the data collection plan and 
help explore data needs from future policy questions related to the National Drug Control Strategy.
